期刊文献+

AML1、AML1-ETO对nucb2基因转录调控活性的影响 被引量:1

Influence of AML1 and AML1-ETO on Transcriptional Regulation of nucb2 Gene
下载PDF
导出
摘要 本研究旨在探讨造血特异转录因子AML1及M2b型急性髓系白血病(AML-M2b)累及的异常融合蛋白AML1-ETO对凋亡相关基因nucb2(nucleobindin-2)启动子转录活性的影响,探索AML1-ETO对AML-M2b型白血病的分子致病机制。利用实时RT-PCR方法在AML1-ETO诱导型白血病细胞株中研究AML1-ETO在转录水平对于nucb2的调控情况;利用ChIP-qPCR方法在AML1-ETO阳性白血病细胞株中研究AML1、AML1-ETO与nucb2基因启动子之间直接的体内相互作用情况;采用双荧光素酶报告基因检测方法,研究AML1、AML1-ETO对nucb2启动子转录活性的调节作用。结果表明:AML1-ETO的表达与nucb2的表达呈负相关;nucb2可能是AML1、AML1-ETO的靶基因;AML1、AML1-ETO皆对nucb2启动子具有转录抑制作用,且AML1-ETO对nucb2抑制更强。结论:nucb2是AML1、AML1-ETO的直接靶基因,AML1、AML1-ETO通过抑制nucb2启动子的活性对其进行转录调控。 This study was purposed to investigate the effect of AML1 -ETO fusion protein resulted from hematopoietic transcription factor ( AML1 ) and acute rnyeloid leukemia M2b ( AML-M2b ) on transcription activity of nucleobindin 2 (nucb2) promoter, and to explore the role of AML1-ETO in molecular pathogenesis of AML-M2b. The real-time RT- PCR was used to study the regulation of AML1-ETO on nucb2 at transcription level in AML1-ETO inducible leukemia cell line, the chromatin immunoprecipitation (CHIP)-based qPCR was used to investigate the direct in vivo interaction between the AML1, AML1-ETO and nucb2 promoter in AML1-ETO positive leukemia cell line, the luciferase report gene assay was used to detect the regulation of AML1, AML1-ETO on the transcription activity of nucb2 promoter. The results showed that the expression level of nucb2 was reduced with the increase of AML1-ETO. The promoter of nucb2 could be bound by both AML1 and AML1-ETO. The promoter of nucb2 was trans-repressed by AML1 and AML1-ETO respectively. It is concluded that the nucb2 is the direct target gene of AML1 and AML1-ETO, the transcription regulation of AML1, AML1-ETO on nucb2 is carried out via repressing its promoter activity.
出处 《中国实验血液学杂志》 CAS CSCD 2009年第6期1482-1486,共5页 Journal of Experimental Hematology
基金 国家高技术研究发展计划资助课题(863计划)(编号2007AA02Z335) 国家自然科学基金(编号30670436)
关键词 AML1 AML1-ETO nucb2 转录调控 M2b型白血病 AML M2b subtype AML1 AML1-ETO nucb2 trans-regulation
  • 相关文献

参考文献17

  • 1Licht JD. AML1 and the AML1-ETO fusion protein in the pathogenesis oft(8;21) AML. Oncogene, 2001 ; 20:5660 -5679.
  • 2Peterson LF, Zhang DE. The 8 ;21 translocation in leukemogenesis. Oncogene, 2004 ; 23:4255 - 4262.
  • 3Balkhi MY, Christopeit M, Behre G, et al. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. Exp Hematol, 2008;36:1449 -1460.
  • 4Peterson LF, Yan M, Zhang DE. The p21Waf1 pathway is involved in blocking leukemogenesis by the t ( 8 ; 21 ) fusion protein AML1- ETO. Blood, 2007 ; 109:4392 - 4398.
  • 5Liu S, Klisovic RB, Vukosavljevic T, et al. Targeting AML1/ETO-histone deacetylase repressor complex : a novel mechanism for valpro- ic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia ceils. J Pharmacol Exp Ther, 2007 ;321:953 - 960.
  • 6Lausen J, Liu S, Fliegauf M, et al. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO. Oncogene, 2006 ; 25 : 1349 - 1357.
  • 7Fliegauf M, Stock M, Berg T, et al. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO. Oncogene, 2004 ;23 : 9070 - 9081.
  • 8Barnikol-Watanabe S, Gross NA, Gotz H, et al. Human protein NEFA, a novel DNA binding/EF-hand/leucine zipper protein. Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Biol Chem Hoppe Seyler, 1994;375:4-97 - 512.
  • 9Kroll KA, Otte S, Hirchfeld G, et al. Heterologous overexpression of human NEFA and studies on the two EF-hand calcium-binding sites. Biochem Biophys Res Commun, 1999 ; 260 : 1 - 8.
  • 10de Alba E, Tjandra N. Structural studies on the Ca^2+ -binding domain of human nucleobindin ( calnuc ). Biochemistry, 2004 ; 43 : 10039 - 10049.

同被引文献15

  • 1Peterson LF, Zhang DE. The 8 ;21 translocation in leukemogenesis.Oncogene, 2004; 23(24) : 4255 -4262.
  • 2Nimer SD, Moore MA. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. Oncogene,2004; 23(24) ; 4249 -4254.
  • 3Licht JD. AML1 and the AML1 -ETO fusion protein in the pathogene-sis of t(8 ;21) AML. Oncogene, 2001 ; 20(40) ; 5660 -5679.
  • 4Maiques-Diazl A, Chou FS, Wunderlich M,et al. Chromatin modi-fications induced by the AML1-ETO fusion protein reversibly silenceits genomic targets through AML1 nd Spl binding motifs. Leukemia,2012; 26(6) : 1329 - 1337.
  • 5Hildebrand D, Tiefenbach J, Heinzel T, et al. Multiple regions ofETO cooperate in transcriptional repression. J Biol Chem, 2001 ; 276(13) : 9889 -9895.
  • 6Lu Y, Xu YB, Yuan TT,ei al. Inducible expression of AML1-ETOfusion protein endows leukemic cells with susceptibility to extrinsicand intrinsic apoptosis. Leukemia, 2006; 20(6) : 987 -993.
  • 7Yan M, Burel SA, Peterson LF, et al. Deletion of an AML1-ET0 C-terminal NcoR/SMRT-interacting region strongly induces leukemiadevelopment. Proc Natl Acad Sci USA, 2004; 101 (49) : 17186 -17191.
  • 8Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relativesin tumourigenesis and cancer therapy. Cell Death Differ, 2011 ; 18(9): 1414 -1424.
  • 9Klampfer L,Zhang J, Zelenetz AO, et al. The AMU/ETO fusionprotein activates transcription of Bcl-2. Proc Natl Acad Sci USA,1996; 93(24): 14059 - 14064.
  • 10Burel SA, Harakawa N, Zhou L, et al. Dichotomy of AML1-ETOfunctions : growth arrest versus block of differentiation. Mol Cell Bi-ol, 2001; 21(16) : 5577 -5790.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部